Willis v. Ochsner Clinic Foundation

140 So. 3d 338, 13 La.App. 5 Cir. 627, 2014 WL 1622611, 2014 La. App. LEXIS 1077
CourtLouisiana Court of Appeal
DecidedApril 23, 2014
DocketNo. 13-CA-627
StatusPublished
Cited by10 cases

This text of 140 So. 3d 338 (Willis v. Ochsner Clinic Foundation) is published on Counsel Stack Legal Research, covering Louisiana Court of Appeal primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Willis v. Ochsner Clinic Foundation, 140 So. 3d 338, 13 La.App. 5 Cir. 627, 2014 WL 1622611, 2014 La. App. LEXIS 1077 (La. Ct. App. 2014).

Opinion

ROBERT M. MURPHY, Judge.

| ¡¡.Defendants/cross-plaintiffs, the Louisiana Patient’s Compensation Fund and the Louisiana Patient’s Compensation Fund Oversight Board (collectively, “the PCF”), appeal from an adverse judgment after a jury trial rendered on November 27, 2012. The judgment awarded damages in favor of plaintiffs, Tyronglia Willis, individually and on behalf of her minor son, Ty’Kevion J. Kidd (collectively, “Plaintiffs”), and in favor of the PCF on its cross-claim asserted against defendants/cross-defendants, Abbott Laboratories, Hospira, Inc. (collectively, “Abbott/Hospira”) and Richard Breland. Plaintiffs and Abbott/Hospira, respectively, also appeal the trial court’s November 27, 2012 judgment. For the reasons that follow, we affirm the judgment in part, and reverse and vacate the judgment in part.

| .FACTS AND PROCEDURAL HISTORY

On March 21, 2005, plaintiff, Ty’Kevion J. Kidd, was admitted to Ochsner Clinic Foundation for heart surgery. At the time of his surgery, Ty’Kevion was approximately two and a half years old. He had no complications during the surgery. After the surgery was concluded, the child was given the medication, epinephrine, intravenously through a triple channel infusion pump known as the Plum XL3 infusion pump (hereinafter “the Pump”). The Pump was manufactured by Abbott Laboratories and provided to Ochsner under a lease agreement with Hospira, Inc., a spinoff corporation of Abbott Laboratories. The Plum XL3 infusion pump allows for the administration of up to three different primary medications to a patient through a plastic I.V. set that includes a plastic cassette. Abbott/Hospira designed the Plum XL3 to protect against the free-flow of medication. Specifically, the Plum XL3 [343]*343incorporates a safety mechanism, called the flow regulator, which automatically stops all flow of medication when the door is opened and the cassette is removed from the pump. This is known as an anti-free-flow device.

On the day of the incident, Dr. Lutifak Kashimawa (also known as “Dr. Luttie”), a pediatric critical care physician, was treating Ty’Kevion in the Pediatric Intensive Care Unit (“PICU”) during his post-operative recovery. At the time Ty’Kevion arrived in the PICU, he was receiving epinephrine through channel C of the Pump. Dr. Luttie remained in the PICU with the child for approximately forty-five minutes. After Dr. Luttie left the PICU, Nurse Christine Brauner McKearnan continued to monitor the child while in the PICU. At 1:45 p.m., Nurse McKearnan received an order from Dr. Luttie to discontinue the administration of epinephrine to the child. At that time, Nurse McKearnan discontinued the epinephrine by turning the Pump off. For approximately one hour after she turned the Pump off, 14Ty’Kevion remained stable. Dr. Luttie ordered Nurse McKearnan to begin transfusing blood to the child. Nurse McKearnan then removed the cassette containing the epinephrine from the Pump, but left the cassette and tubing connected to Ty’Kevion, and began to transfuse blood to Ty’Kevion through channel C of the Pump.

Shortly thereafter, around 3:00 p.m., Nurse McKearnan informed Dr. Luttie that Ty’Kevion was hypertensive, his pulse was increasing and he was not responding to pain medication. When Dr. Luttie arrived in the PICU, she noted that blood was coming out of the child’s breathing tube and quickly began to assess the child to determine what was wrong. Approximately twenty minutes later, the other nurse assisting Dr. Luttie, Nurse Emily Stolpa, looked at the Pump’s clear plastic drip chamber and noticed that the epinephrine bag was still flowing into the child. Nurse Stolpa immediately stopped the flow of epinephrine at that time. However, approximately three fourths of the epinephrine bag had already flowed into the child.

It was later determined that at some point after Nurse McKearnan removed the cassette containing epinephrine from the Pump, the Pump’s flow regulator malfunctioned and failed to automatically stop the flow of epinephrine due to a broken door roller in channel C of the Pump. The free-flow of epinephrine into Ty’Kevion caused his lungs to hemorrhage, which ultimately led to cardiac arrest and permanent anoxic brain injury, including right watershed infarcts, bilateral basal ganglia infarcts and cerebellar infarcts.

On February 17, 2006, the child’s mother, Tyronglia Willis, filed a medical malpractice action against Ochsner on behalf of her child and in her own name. Plaintiffs subsequently amended their petition on March 15, 2006, and again on March 17, 2006, to allege claims under the Louisiana Products Liability Act ¡ S(“LPLA”) against Abbott/Hospira and Richard Breland, the employee of Hospira who was in charge of maintaining the Plum XL3 pumps provided to Ochsner under the lease agreement. Subsequently, Ochsner agreed to tender the $100,000 statutory limit to Plaintiffs under La. R.S. 40:1299.44(0) of the Louisiana Medical Malpractice Act (“LMMA”), thereby admitting liability. On May 30, 2007, Plaintiffs filed a petition seeking court approval of Ochsner’s $100,000 tender, as well as a finding that said tender constitutes an admission of liability under La. R.S. 40:1299.44(0). Plaintiffs’ petition further sought to reserve their right to proceed against the PCF for damages in excess of the $100,000 statutory limit.

[344]*344In answering Plaintiffs’ petition on June 13, 2007, the PCF also asserted a cross-claim for indemnity and/or contribution against Abbott/Hospira and Richard Bre-land. Specifically, the PCF alleged that Abbott/Hospira and Breland were jointly, severally and solidarity liable for Plaintiffs’ injuries and damages, and denied any joint, several or solidary liability on behalf of the PCF. The PCF further alleged the Pump was unreasonably dangerous and/or defective at the time of its manufacture, and that it caused Plaintiffs’ damages, in whole or in part. As a result, the PCF alleged that in the event that the PCF was cast in judgment as a result of the allegedly defective pump manufactured by Abbott/Hospira, the PCF would be entitled to indemnity from Abbott/Hospira for the full extent of any such damages.

On August 31, 2007, the trial court signed a consent judgment which (1) approved the settlement between Plaintiffs and Ochsner for the statutory limit of $100,000 as an admission of liability under La. R.S. 40:1299.44(0; (2) authorized Plaintiffs to proceed against the PCF with their claim for damages in excess of $100,000; and (3) reserved the PCF’s rights to contest Plaintiffs’ claims for excess damages.

| fiDuring a January 25, 2012 status conference, the parties agreed to set the matter for trial on August 6, 2012. Subsequently, on May 4, 2012, Plaintiffs, Abbott/Hospira and Richard Breland filed a joint motion to dismiss Plaintiffs’ claims against Abbott/Hospira and Breland with prejudice due to a confidential settlement between the parties. Accordingly, the trial court issued an order on May 7, 2012, dismissing Plaintiffs’ claims against Abbott/Hospira and Breland with prejudice, but reserving Plaintiffs’ claims against Ochsner, as a nominal defendant, and against the PCF.

On the following day, Plaintiffs filed a motion to strike the PCF’s cross-claim for indemnity against Abbott/Hospira. In their motion to strike, Plaintiffs asserted that the PCF is prohibited from maintaining a claim for indemnity against Abbott/Hospira because as joint tortfeasors, Abbott/Hospira and the PCF would only be held liable for their respective portions of fault under the comparative fault principles of La. C.C. 2323.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Warner v. USAA Gen. Indem. Ins. Co.
237 So. 3d 1241 (Louisiana Court of Appeal, 2017)
Deykin v. Ochsner Clinic Foundation
219 So. 3d 1234 (Louisiana Court of Appeal, 2017)
Oregan v. Cashio
220 So. 3d 845 (Louisiana Court of Appeal, 2017)
Alexander v. La. State Board of Private Investigator Examiners
211 So. 3d 544 (Louisiana Court of Appeal, 2017)
Williams v. Walgreen Louisiana Co.
168 So. 3d 812 (Louisiana Court of Appeal, 2015)
Bass v. State
167 So. 3d 711 (Louisiana Court of Appeal, 2014)
Triche v. McDonald's Corp.
164 So. 3d 253 (Louisiana Court of Appeal, 2014)

Cite This Page — Counsel Stack

Bluebook (online)
140 So. 3d 338, 13 La.App. 5 Cir. 627, 2014 WL 1622611, 2014 La. App. LEXIS 1077, Counsel Stack Legal Research, https://law.counselstack.com/opinion/willis-v-ochsner-clinic-foundation-lactapp-2014.